ArticleAnnals of clinical and translational neurology2022
Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis.
Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Toward a global research agenda for preventing multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.Clinical & translational immunology · 2026Article
- Anticipating Clinical Onset in Multiple Sclerosis: Challenges and Opportunities.Journal of personalized medicine · 2025Review
- Health Care Use Before Multiple Sclerosis Symptom Onset.JAMA network open · 2025Article
- Phenotyping Healthcare Use 2-3 Decades Before the First Multiple Sclerosis Demyelinating Event.Annals of clinical and translational neurology · 2025Article
- Health care use preceding pediatric multiple sclerosis: A population-based study from Ontario, Canada.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern.Journal of neurology · 2025Article
- Higher healthcare use before paediatric multiple sclerosis onset: a nationwide cohort study.Brain communications · 2025Article
- Temporal Dynamics of Plasma Neurofilament Light in Blood Donors With Preclinical Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women.The journal of headache and pain · 2024Article
- An autoantibody signature predictive for multiple sclerosis.Nature medicine · 2024Article
- Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Adverse Childhood Experiences and the Risk of Multiple Sclerosis Development: A Review of Potential Mechanisms.International journal of molecular sciences · 2024Review
- Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.Brain : a journal of neurology · 2024Article
- Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.Nature reviews. Neurology · 2023Review
- Serum neurofilament light chain in multiple sclerosis: from biological signal to clinically informed decision-making.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Axonal loss is the main cause of irreversible disability in multiple sclerosis (MS). Serum neurofilament light (sNfL) is a biomarker of axonal disintegration. In this nested case-control study, blood samples from 519 presymptomatic persons (age range 4-39 years) who later received an MS diagnosis showed higher sNfL concentrations than 519 matched controls (p < 0.0001), noticeable at least 10 years before clinical MS onset. Mean values for pre-MS and control groups were 9.6 pg/mL versus 7.4 pg/mL 0-5 years before onset, and 6.4 pg/mL versus 5.8 pg/mL 5-10 years before onset. These results support that axonal injury occurs early in MS pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.